CLINICAL TRIALS PROFILE FOR METROGEL-VAGINAL
✉ Email this page to a colleague
All Clinical Trials for METROGEL-VAGINAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01020396 ↗ | Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis | Completed | Teva Pharmaceuticals USA | Phase 1/Phase 2 | 2002-01-01 | The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal® metronidazole vaginal gel, 0.75% to establish clinical equivalence in the treatment of bacterial vaginosis. |
| NCT01020877 ↗ | Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects | Completed | Teva Pharmaceuticals USA | Phase 1 | 2001-11-01 | The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects. |
| NCT02376972 ↗ | Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis | Terminated | Parexel | Phase 2 | 2015-04-01 | THE STUDY HAS BEEN DESIGNED TO COMPARE THE EFFICACY OF TWO DOSES (25 MG AND 100 MG) OF RIFAXIMIN VAGINAL TABLETS VERSUS PLACEBO IN SUBJECTS WITH BACTERIAL VAGINOSIS |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for METROGEL-VAGINAL
Condition Name
Clinical Trial Locations for METROGEL-VAGINAL
Trials by Country
Clinical Trial Progress for METROGEL-VAGINAL
Clinical Trial Phase
Clinical Trial Sponsors for METROGEL-VAGINAL
Sponsor Name
